Get started

Biotech

Biotech Sector Likely To Bounce It's been a rough ride for bios lately, but a reversal could be coming very soon. As you can see in the chart, $XBI, the biotech ETF that I like, has fallen to an important VWAP and to the 50% retracement. Today we bounced off of that level, forming a sort of hammer candle on this Heikin Ashi chart. This fund is also currently at the bottom of the daily RSI, which historically is a good sign. This could mean we see a bounce soon, possibly to $150 within the next couple of weeks. I may post more on biotechs now that they should be getting hotter, so be sure to like and follow for more ideas like this :) Good Luck!
AMEX:XBILong
by Investor4321
1
Under Major revaluationWouldn't be surprised to see this stock break all time highs in next few months and in the next 12-months $50+. * Key notes: 2nd generation Covid Vaccine sponsored by NIAID that's being conducted through infectious diseases clinical research consortium (IDCRC). Established collaboration with Gilead Sciences to develop a vaccine-based immunotherapy as part of Gilead's efforts to find a 'curative treatment for human immunodeficiency virus" (HIV) infection, and received $60 million in proceeds as part of the collaboration for GRTS HIV candidate. More candidates in clinic on their website. Very bullish accumulation going on after test of $35 (red horizontal line). See my other picks! $KMPH $VBIV $BCRX $GRTS Disclaimer: This is not a buy or sell recommendation. I am not a financial analyst. This information should be used for educational purposes only.
GLong
by follow_the_money
BACK IN $IBIO @ 1.57 Target 1.91 for 21.66% $IBIO Target 1.91 for 21.66% Or next add level is at 1.23 Good fun!! Sold at 2.19 two days ago and back in at 1.57... let's go!! — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
AMEX:IBIOLong
by SPYder_QQQueen_Trading
2
ADDED to $SYRS New Target 9.22 for 26.13% $SYRS Target 9.22 for 26.13% Or next add level is at 5.40 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:SYRSLong
by SPYder_QQQueen_Trading
3
$RMED entry PTs 3.45-3.50 (ER next Tues: 5/11/2021) PTs 4-9Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
RLong
by UnknownUnicorn19246015
$VXRT entry PT 7-8 PT Target PTs 14-17-22Trend-base Fib Extension... Why Vaxart Stock Is Surging Today Investors are excited about the company's experimental COVID-19 vaccine. What happened Shares of Vaxart (NASDAQ:VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%. So what A phase 1 study showed Vaxart's vaccine to potentially be protective against COVID-19, as well as a broad array of other coronavirus-induced illnesses, such as SARS, MERS, and the common cold. "Our vaccine's immune response appears very different than that seen from the leading injectables: mucosal antibodies rather than serum antibodies, and more potent T-cell responses," Vaxart CEO Andrei Floroiu said in a press release. T-cells are a type of white blood cells that can seek out and kill virus-infected cells. They are a vital part of the body's ability to generate an adaptive immune response to specific pathogens. Vaxart's drug produced a stronger T-cell response than Pfizer and Moderna's injectable vaccines, according to Vaxart's chief scientific officer, Dr. Sean Tucker. Now what Should Vaxart's vaccine candidate prove to be safe and effective in later-stage clinical trials, it could become a welcomed new tool in the battle against COVID-19. In such a scenario, the drug would also provide Vaxart with a powerful new revenue and profit driver. Joe Tenebruso (TMFGuardian)
NASDAQ:VXRT
by UnknownUnicorn19246015
ZOM hits lows and bounces back hardI will admit if a trade doesn't come to what I think it will do I'll say im wrong, but that's the beauty of tradingview and how we can share ideas. I still remain skeptical of the current price action and have give a range of price movement of the current price. As a trader watching on the sidelines I still believe for a new/long term trade is wait till earnings. This movement up is unknown why its pumping but a few reasons may be the cause Why is this pumping? -Whole market is recovering at this time and biotech/pennystocks are feeling some love which were one of the worst hit sectors. -Past buyers bought the dip and has had an amazing bounce back, which I will talk about in the TA portion. -The sentiment around ZOM was negative people panic sold from $1.15 too .73, which caused the sellers to be exhausted. With no more sellers the price rebounded and fomo struck. TA: Its interesting cause the chart goes aganist the news, so an idea of this is a short squeeze to exit positions. Who knows -April 22, we skyrocketed towards the 50ema and held causing a bullish reversal in the RSI as it held -RSI leads bullish with the current movement of the stock -Resistance is at 1.41, but could say its at 1.18 with past high or go off the emas, which is at 1.13 and 1.29 -Support would be at the 50 ema .97/.96 or slightly before at 1.01 which could be a dip opportunity. -If the trade goes south you could experience a 29%-74% lost with an upside of 124% going back to ath Final thoughts I'll remain skeptical of this pump till er, since again it could be a pump to have people fomo and sell into the buyers or just exhaustion from the months of downward movement. With TA however it remains bullish/neutral
AMEX:ZOM
by nathanielx9
$BCTX PT 4-4.50BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
NASDAQ:BCTXLong
by UnknownUnicorn19246015
$AGSO Massive Subsidiaries And Upcoming Catalysts. PT - $10+MASSIVE DD Packet Compilation created today of upcoming events and catalysts: t.co NRG currently has 20+ trucks operating in 9 states across the Mid south and Western states. NRG Dynamics is a modern fleet coupled with forward thinking when it comes to technology and operations. They operate completely cloud-based. Considered a specialized carrier with primary focus on MC-331 Tanker, Hauling Liquid Petroleum Gases with Access Agreements or almost every loading facility in the West. During the summer months, part of the fleet is converted to run liquid asphalt (hot oil) and emulsions for road construction. ABOUT US (titannrg.com) NRG RAIL: - RailYard officially turned over for use to NRG Rail from Union Pacific Nov. 20’ The company will be transloading (pictured above) until they begin Phase 1 of the terminal construction which has already been permitted. The Rail yard is composed of 18 rail spots currently and will also feature 9 dual sided towers holding 1.2M gallons of LNG storage on site. - Phase 1 begins with 5 towers, 360k gallons of storage, and two loading racks installed in '21. At that time, the transloader will be retired and the operation will commence operating as a Liquefied Petroleum Gas terminal in Tucson, Arizona. Ape Fuels: - Retail propane provider serving southern Arizona since 2001 by new board of directors member Ginger Cunningham. 1500 leased tanks, 2000+ customers and additional service trucks. Vespene LLC : - Originated in 2011, Vespene LLC provides Titan NRG Partners with wholesale products. It purchases products from the refineries and other various suppliers in the area. You can find the rest of the massive DD in the link provided!!! PT $10+
ALong
by StockGuild
MRNA & end of the bulls?MRNA has had a few wild weeks going up from $120 to $170. I believe this could be the end of the bullishness and it may do a correction. Why do I believe this could happen? MRNA hit historic resistance of $170, after hitting that mark it began dropping. This resistance seems like it can hold. RSI is bounced off the 70 mark on the daily chart. RSI is overbought on the 4HR chart EMA's are beginning to cross over on the hour charts. This could be a tiny correction and just bounce off $160 before continuing its path to $200 so I would keep a close eye on the stock. What I am looking for right now is: 1st support - $160 2nd support - $139_$145 3rd support - $120 At this point MRNA going back down to $100 or even lower seems incredibly unlikely. Moderna's earnings arent too far away so that could act as a catalyzer that will continue the growth. In short I believe that MRNA could have hit the resistance and it will either go down to the listed supports or if it stays in these levels then it will most likely stay like this till earnings come which will tell what direction it is going to go from here. Please comment down your ideas and thoughts on this, I would appreciate any criticism you may have on the charts and analysis, and looking forward to your comments! I am not a financial advisor, these are my personal ideas an thoughts please do your own research before buying a stock.
NASDAQ:MRNAShort
by Geckie
10
Catalent Is about to beat earnings?Now I've been watching Catalent, since they partnered up with one of the stocks I hold for a COVID treatment. Novan. Doing a quick glance at CTLT I noticed a TA pattern known as a double bottom and with certain catalyst coming out, maybe its about to run up and leave this bearish trend. News -ER is in 14 days -They have partnered up with Novan to design the injection of Novan's product that can treat/reduce spread of COVID by 90%, which comes out in Q3. TA As you can see the curve lines represents the two bottoms and the top with two white lines pointing at support points. Now note that this could be just a trading zone, yet we will get into the bullish argument. -MACD a cross over is turning bullish -RSI is rising, yet would need to break 52.47. Also if you want, you could say its already bullish on the RSI with a small error margin in TA. -Resistance would be at 110.87, 114.67, and finally the high of 125-127 -Support is at 106.89 and 100.52. -The emas aren't bad with it ending on top of the 50ema which leans bullish in the short term. -VPVR levels are really high at where it closes today with the resistance in the VPVR at 113 and the support at 106-107 Final thoughts It leans bullish if the Double Bottom pattarn plays out and could see it run up nicely on ER. This ER is Q2 for Catalant, so the COVID play will come out sometime after.
CLong
by nathanielx9
NOVAN a biotech stock that might fly very soonDisclaimer: I do own a position and you may want to do your own DD, since this post maybe bias even if its not. Please do your own research. Novan is a pennystock biotech that picked up steam last fall like many pennystocks, but through out 2021 stocks have been getting hit with biotech and pennystocks/low caps being the worst hit sectors. Cathie Woods states in her investment strategy is buy sectors that are hurt the most and that have the protentional to move higher. Novan is its own patient product of nitric oxide throughout United States and Europe and wants to expand on it. News -March 29th The CEO bought 70,000 shares, which is bullish when the CEO is buying -Voting has started and results come in on May 4th. There are many things in here such as increasing the share count by 15million, which shares off 200million doesn't seem much. This doesn't mean shares will get dumped it just means they have the option to do offerings in the future. -Q2 (current quater that last till the end of May possibly June) they will get the results of sb206 B, which looks positive. sb206 will the first every treatment for a skin condition called Mollescum. In doing a quick google search, business wire estimates in 2017 there was over 12million cases and half was in the United States. Googling Mollescum cases in the United States go up 200k a year. Now how does Novan fit into this? Well they would be the only FDA treatment on the market, which would send market shares shoring to a billion dollar valution in a short period time (pt would be around $7). -They also partnered up with Catalent to develop a COVID treatment, which has shown with Novan's product that can reduce the spread of Covid of around 90%. Which catalyst would send Novan to a 10billion dollar valuation, but its up to Catalent. This product is suppose to hit in Q3/Q4, but leans more of a Q3. Pipeline -Like ZOM, Novan is also entering the pet care field, but not a device to do testing. On the last webinar investor prestation, they are working to test their product to help skin dieses in dogs and atm are targeting K9s. This would pickup after sb206 and would get more news sometime around q4 or early next year (most likely when they get the marketing of sb206 going). TA: Now that was alot of "shilling," but its great to know the protentional of a mid/long term play of Novan. It begs the question is if the pennystock is under the radar. Zack Investments and a big advocate in Novan and gave Novan a pt of $4, but 2021 hit and crashed the market. So heres some TA that might help you keep your risk at check if you enter. -Resistance in the short term is at $1.08, but closing was $1.10 on April 16, so $1.13 would act more of a challenge. After that is $1.32, $1.45, and then $1.63. With tight consolidation in the past between $1.63-$1.76, breaking that could shoot up to $1.96 or $2+ -Support: support is tricky cause we are free falling like most pennystocks such as ZOM. I would say a micro 5min scale, Every $0.02 is support, but on the hourly we could fall as low $0.96, but its unlikely. Last year we gain compliance of the $1, so there's a lot of buyers from here too $0.96 that will keep it above $1. Now if we get a negative catalyst we could drop too $0.86-$0.81 -MACD leans bearish as we look for a reversal -RSI is oversold and leans bullish for a bounce back with resistance at 46.89. If people wondering where I get these RSI lines, I look at where its uptrending and make a guess where it breaks and the price starts dropping and the RSI goes from overbought to oversold levels. -VPVR means shit like ZOM's TA, but in the past a lot of support at these levels in the past. -Current EMA 50 is at $1.27, 128 is at $1.40, and the 200 is at $1.45. Final Thoughts Biotechs are risky, but with the CEO buying at $1.40 and seeing the price way below that is a sign to toss in some money or go all in. Its up too you, but I would take the bet and wait this storm out. The confidence between ZOM and Novan is I would pick a stock that has a bigger upside in a near term timeline. Again its best too do your own your research.
NLong
by nathanielx9
3
Biotech Double Bottom (+ Divergence & Bollinger Reversal)Technical Analysis 1. As you see in the chart, we have tested the 200ema 3 times in the past; and it has not trade below it since April 2020. We have made a spinning-bottom on a downtrend, coincidental with a 4th test of the 200ema. 2. RSI and OBV show a positive divergence as the bottom from 2 weeks ago (Test #3) was at a lower level. 3. Bollinger Bands give us another bullish signal, as the first low (Test #3) was outside the lower BB, and the second low (Test #4) was inside the lower BB. Trade Setup A break below Test #3 which is $142.47 could be a potentially good place to set a stop-loss exit. Short-term target to the upside --> $160.5 Mid-term target to the upside --> $170 Trade with care
NASDAQ:IBBLong
by dorfmanmaster
IFRX Technical Analysis 🧙InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:IFRXLong
by yura_trades
Don't fomo into MRNA...yetMRNA made a huge leap on Friday going front $133 to $144. I believe MRNA will resume bullishnes as long as the market remains stable and bullish BUT, MRNA could drop to around $135 before continuing to go up. It still has a way to go on the RSI indicator and EMA's still haven't passed over. If MRNA exists the channel be ready for more mooning to come. Disclaimer: I am not a financial advisor and this is purely my opinion and thought about this stock, do your own research before going into MRNA.
NASDAQ:MRNA
by Geckie
4